SCHEMBL18620550

SCHEMBL18620550

CCc1cc(N)nc(N)c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 6/20 0.42
▸ NOS3 P29474 5/20 0.42
▸ NOS1 P29475 4/20 0.41
▸ HTT P42858 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ GABRP O00591 1/20 0.40
▸ GABRD O14764 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRB1 P18505 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40
▸ GABRB2 P47870 1/20 0.40
▸ GABRA4 P48169 1/20 0.40
▸ GABRE P78334 1/20 0.40
▸ GABRA6 Q16445 1/20 0.40
▸ GABRG1 Q8N1C3 1/20 0.40
▸ GABRG3 Q99928 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21425714 0.80 KDM4E (0.42) NOS2NOS3NOS1HTTPOLB
SCHEMBL28488593 0.75 P2RX3 (0.39) HTTPOLBDHFRALDH1A1
SCHEMBL18315118 0.71 NOS2 (0.45) NOS2NOS3NOS1HTTGABRP
SCHEMBL10400002 0.70 GABRP (0.46) NOS2NOS3NOS1GABRPGABRD
SCHEMBL20909174 0.70 NOS2 (0.39) NOS2NOS3NOS1GABRPGABRD
SCHEMBL17232460 0.70 NOS2 (0.44) NOS2NOS3NOS1GABRPGABRD
SCHEMBL27612200 0.69 HTT (0.50) NOS2NOS3NOS1HTTPOLB
SCHEMBL8259992 0.69 HEXA (0.56) HTTPOLBTDP1DHFRALDH1A1
SCHEMBL2955353 0.69 TDP1 (0.43) NOS2NOS3NOS1POLBMAPT
SCHEMBL22063663 0.68 NOS2 (0.42) NOS2NOS3NOS1HTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017040451-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MYERS SQUIBB COMPANY (US) 2017-03-09 — — WO disclosed
Send feedback